Adaptive Biotechnologies/$ADPT
1D1W1MYTD1Y5YMAX
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
- Ticker
- $ADPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 624
- Headquarters
- Seattle, United States
- Website
- www.adaptivebiotech.com
ADPT Metrics
BasicAdvanced
$4.1B
-
-$0.41
2.09
-
Price and volume
Market cap
$4.1B
Beta
2.09
52-week high
$26.16
52-week low
$12.00
Average daily volume
2.6M
Financial strength
Current ratio
4.795
Quick ratio
4.51
Long term debt to equity
266.607
Total debt to equity
272.464
Interest coverage (TTM)
-3.26%
Profitability
EBITDA (TTM)
-21.327
Gross margin (TTM)
46.94%
Net profit margin (TTM)
-20.73%
Operating margin (TTM)
-12.16%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-4.12%
Return on equity (TTM)
-38.76%
Valuation
Price to revenue (TTM)
13.097
Price to book
28.93
Price to tangible book (TTM)
179.29
Price to free cash flow (TTM)
-167.884
Free cash flow yield (TTM)
-0.60%
Free cash flow per share (TTM)
-0.155
Growth
Revenue change (TTM)
50.13%
Earnings per share change (TTM)
-49.41%
3-year revenue growth (CAGR)
17.56%
3-year earnings per share growth (CAGR)
-32.39%
What the Analysts think about ADPT
Analyst ratings (Buy, Hold, Sell) for Adaptive Biotechnologies stock.
ADPT Financial Performance
Revenues and expenses
ADPT Earnings Performance
Company profitability
ADPT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.